Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avanafil - VIVUS

Drug Profile

Avanafil - VIVUS

Alternative Names: RAZATUS; Spedra; Stendra; TA-1790; Zepeed

Latest Information Update: 21 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tanabe Seiyaku
  • Developer Acerus Pharmaceuticals; JW Pharmaceutical; Menarini; Petros Pharmaceuticals; VIVUS
  • Class Erectile dysfunction therapies; Pyrimidines; Small molecules
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Erectile dysfunction

Highest Development Phases

  • Marketed Erectile dysfunction
  • Discontinued Female sexual dysfunction; Premature ejaculation

Most Recent Events

  • 15 Nov 2022 Acerus Pharmaceuticals announces intention to re-submit NDA to Health Canada for Erectile dysfunctions
  • 14 Dec 2021 VIVUS completes a phase I trial in Healthy volunteers (In adults)
  • 09 Nov 2021 Acerus Pharmaceuticals plans to launch avanafil for Erectile dysfunction in Canada, in 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top